Pharmacodynamic properties of beta-adrenergic receptor blocking drugs in man.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000526:Alprenolol / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002395:Catecholamines / Q000037:antagonists & inhibitors; D006019:Glycolysis / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006329:Heart Conduction System / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D050356:Lipid Metabolism; D010096:Oxprenolol / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D005082:Physical Exertion; D010869:Pindolol / Q000494:pharmacology; D011217:Practolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011802:Quinidine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects; D012039:Regional Blood Flow / Q000187:drug effects; D012083:Renin / Q000097:blood; D013329:Structure-Activity Relationship; D014666:Vasomotor System / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D002395:Catecholamines; D011941:Receptors, Adrenergic; D010096:Oxprenolol; D000526:Alprenolol; D011433:Propranolol; D010869:Pindolol; D012083:Renin; D011802:Quinidine; D011217:Practolol